Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.

GUIDANCE:

Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310 million, versus the consensus of $249.15 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown